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prostate ultrasound images with either a Foley or gel were fused 
and analyzed. The catheter tends to take a path of least 
curvature and is thus located in the anterior urethra. At mid-
prostate the difference is most pronounced with the posterior 
edge of the catheter located up to 7 mm anterior to the posterior 
aspect of the gel-filled urethra. Urethra V115% was higher when 
the urethra was defined with gel. Median V115% was 0 cc (0-0.03) 
with catheter compared to 0.03 cc (0-0.53) with gel (p = 0.02) 
and translated to a median V115% of 0% (0-2.14) versus 3.23% (0-
20.95) (p = 0.003), respectively. Only one patient when analyzed 
with the gel had a V118% > 10%(16.6%) and three had a V125% > 
0 cc (p = 0.31). The urethral volume was 1.4 cc (1.04-1.85) using 
the 6mm circle and was 1.22 cc(0.7-2.53) when using aerated gel 
(p = 0.522). At the prostate base and apex the smaller diameter 
of the urethra makes visualization with gel alone difficult. 
Conclusions: Using a Foley catheter for urethral identification 
and dose prescription underestimates the dose that is actually 
received by some patients. Urethral curvature differs from the 
Foley catheter, especially at mid gland where the catheter rides 
anteriorly. A standard 6 mm circle does not represent the entire 
urethral volume. Although we have not observed unexpected 
toxicity, we will continue to monitor actual urethral dose to 
correlate with toxicity in future patients. In the meantime, use 
of a catheter is the most reliable means of visualizing the entire 
length of the prostatic and membranous urethra. Consideration 
could be given to expanding the 6 mm circle in the posterior 
direction in mid-gland. 
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Purpose: To evaluate long-term biochemical control (bRFR) and 
radiation toxicity for men with localized prostate cancer treated 
with two moderately hypofractionated IG-IMRT regimens. 
Methods and Materials: Eligible consenting men with T1c-T3a Nx 
M0 prostate cancer were enrolled in a Phase II trial and received 
IG-IMRT to a risk-adapted volume that included prostate +/- 
seminal vesicles at 3 Gy per fraction, 5 days per week in 
sequential cohorts to a total dose of either 60 Gy or 66 Gy. Late 
gastrointestinal (GI) and genitourinary (GU) toxicity were 
recorded at each follow up using the Radiation Therapy Oncology 
Group criteria and biochemical failure was scored using the PSA 
nadir+2 criteria. Outcome estimates were calculated using the 
Kaplan-Meier method and log rank test. Early stopping rules 
terminated accrual to the 66 Gy cohort due to excessive Grade 
3-4 late toxicity. 
Results: Ninety-six men received 6 0Gy and 28 received 66 Gy. 
Androgen deprivation therapy (3-36 months duration) was used 
in 10% of men in both cohorts. For each cohort, the median age 
was 71 years (60 Gy) and 70 years (66 Gy). Low or intermediate-
risk presentation was respectively 27% and 65% (60 Gy) and 25% 
and 71% (66 Gy). Median follow up was 128 months (60 Gy) and 
108 months (66 Gy). The five- and eight-year bRFR for 60 Gy and 
66 Gy were respectively 83% and 67% versus 88.5% and 73.4% (p 
= 0.224). For each cohort, five (60 Gy) and one (66 Gy) subjects 
died from disease. Overall five- and eight-year cumulative late 
Grade 1-4 GI toxicity for 60 Gy versus 66 Gy were respectively 
21.2% and 21.2% versus 44.6% and 48.9% (p = 0.004). Cumulative 
late Grade 1-4 GU toxicities were respectively 23.8% and 32.8% 
versus 40.4% and 51.4% (p = 0.048). Cumulative five- and eight-
year late Grade 3-4 GI toxicity for 60 Gy and 66 Gy were 
respectively 1.1% and 1.1% versus 11.5% and 11.5% (p = 0.01). 
Cumulative five- and eight-year late Grade 3-4 GU toxicity for 60 
Gy and 66 Gy were respectively 0 and 1.5% versus 3.7% and 3.7% 
(p = 0.41). At last follow up in the 60 Gy cohort there were no 
Grade ≥ 3 late GI toxicities and one Grade 3 late GU toxicity. In 
the 66 Gy cohort there was one Grade 4 late GI toxicity and one 
Grade 4 late GU toxicity. 
Conclusions: Moderate hypofractionation to 60 Gy was 
associated with modest late toxicity and provided excellent five-
year bRFR for our patients, although failures continued to be 
observed with subsequent follow up. Dose escalation to 66 Gy 
was associated with significantly worse late GI and GU toxicity 
without an apparent improvement in bRFR. 
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Purpose: To determine the impact of pre-treatment interstitial 
lung disease (ILD) on radiation pneumonitis and overall survival 
(OS) in patients treated with lung SBRT. 
Methods and Materials: Patients treated with lung SBRT 
between October 2004 and July 2015 at our institution were 
included. Pre-treatment CT scans were reviewed by experienced 
thoracic radiologists and interstitial changes including ground 
glass opacities (GGO), reticulations and honeycombing were 
scored and involvement to the nearest 5% was used to calculate 
Washko and Kazerooni scores. Radiation pneumonitis (RP) was 
prospectively documented using the CTCAE V4.0 criteria. Pre-
treatment imaging characteristics, lung and heart dose 
parameters and clinical variables including smoking status and 
pulmonary function were assessed by univariate (UVA) and 
multivariate analysis (MVA). OS was assessed by log rank test and 
impact of ILD on overall survival was assessed by Cox regression. 
Results: Five hundred and forty-two patients were assessed with 
56 having evidence of interstitial changes on pre-treatment 
scans. These included 12 cases of usual interstitial pneumonia 
(UIP), 18 cases of possible UIP, nine cases of non-specific 
interstitial pneumonia and 17 cases of age-related reticulations 
thought to be unrelated to ILD. RP was significantly higher in the 
39 patients with ILD (Grade ≥ 2 20.5% versus 5.8%, p < 0.01; Grade 
≥ 3 10.3% versus 1.0%, p < 0.01). Of the three cases of Grade 5 
RP observed in our series, two had imaging features of ILD. On 
UVA, radiographic evidence of ILD, Washko score, lung 
parameters (V5/V10/V15/V20/mean lung dose) and performance 
status were significant predictors of Grade ≥ 2 RP. Age-related 
reticulations were not associated with increased toxicity. On 
MVA, ILD (OR 5.18, p < 0.01) and mean lung dose (OR 1.003, p < 
0.01) were predictors of RP. ILD did not significantly affect OS 
on UVA or MVA. Median survival was 26.5 months in the ILD cohort 
and 36.6 in the ILD negative cohort (p = 0.09). 
Conclusions: Radiographic evidence of ILD is a significant risk 
factor for RP in patients treated with lung SBRT, but did not 
impact OS. CT scans should be reviewed for evidence of ILD prior 
to SBRT and involvement of respirology for management is 
essential. If ILD patients are treated with SBRT, they should be 
monitored closely for RP. 
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Purpose: Real-time transrectal ultrasound (TRUS) image 
guidance for prostate high dose-rate brachytherapy (HDR-BT) 
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enables a high degree of accuracy in dose delivery. Nevertheless, 
the identification of a dominant intraprostatic lesion (DIL) on 
TRUS is challenging. With the advent of multiparametric 
magnetic resonance imaging (mpMRI), it is possible to identify a 
location of excess of tumour cells location that are especially 
aggressive. Unfortunately the geometry of the prostate on TRUS 
and on mpMRI may be different, requiring a deformable fusion to 
map a DIL identified on mpMRI. This study evaluates a novel 
automated deformable registration algorithm developed in-
house for mpMRI-to-TRUS DIL fusion. 
Methods and Materials: Five patients with low- and 
intermediate-risk prostate cancer treated as part of a Phase II 
clinical trial approved by our institutional research ethic board 
were included in this study. All patients had a predominant 
PIRADS 4-5 intraprostatic nodule identified on mpMRI. An 
automated deformable registration was then accomplished as a 
three-part process: 1) convert each of the two datasets into 
distance maps; 2) register the MRI distance map to the TRUS 
distance map using a rigid affine transformation; and 3) perform 
a basis-spline (B-spline) deformable registration between the 
two datasets. An MRI assisted TRUS based real-time prostate 
HDR-BT was delivered afterward. A single fraction of 19 Gy 
prescribed as a minimal dose to the prostate was delivered with 
the DIL to receive a D90 ≥ 23 Gy up to 28 Gy (tertiary objective). 
To evaluate the accuracy of the automatic deformable 
registration algorithm, a radiation oncologist was asked to 
cognitively register the lesion on mpMRI on the intraoperative 
TRUS dataset. Correlation between the observer’s contours and 
the automated contours were compared using the Dice similarity 
coefficient. The average distance from the edges of the observer 
and automated contours were reported in each of the cardinal 
directions.  
Results: The mean Dice coefficient for the prostate volumes was 
0.88 ± 0.01. The mean Dice coefficient for the DIL was 0.76 ± 
0.04. The mean difference in the anterior and posterior edge of 
the automated versus human contours was 0.93 ± 0.89 mm and 
0.26 ± 0.26 mm respectively. The mean difference in the superior 
and inferior edge of the automated versus human contours was 
2.19 ± 1.72 mm and 1.55 ± 1.44 mm respectively. The mean 
difference in the lateral edge of the automated versus human 
was 1.13 ± 0.38 mm as opposed 2.58 ± 1.8 mm in the medial 
edge. 
Conclusions: The automated deformable registration algorithm 
objectively and reliably transposes the DIL identified on mpMRI 
imaging into the TRUS based prostate HDR-BT workflow. Caution 
should be exercised when using automated contour based 
algorithms, with careful QA of the resultant co-registration. 
Particular scrutiny should be directed at the sup-inf and med-lat 
extents of the DIL resulting from the fusion. 
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Background:  Radiotherapy is an effective and comparably low-
cost cancer treatment. It has been estimated that 50% of cancer 
patients require radiation treatment. Lung cancer is the most 
commonly diagnosed cancer globally, and 77% of patients 
diagnosed with lung cancer will need radiotherapy. Despite this, 
evidence from around the world suggests that radiotherapy for 
lung cancer and other cancers continues to be under-utilized for 
reasons unrelated to patient need. Traditionally in radiation 
oncology, the majority of research has been focused on 
improving scientific knowledge and technical aspects of therapy. 
However, achieving the outcomes that these innovations allow is 
often hampered by system factors such as the complexities of 
matching demand for radiotherapy with supply of radiotherapy 
services. Consequently, there is a great need to measure actual 
and optimal use of radiotherapy and to identify and research 
modifiable factors that contribute to sub-optimal utilization of 
multimillion-dollar high-precision radiation treatment centres. 
The lack of availability of comprehensive information on 
characteristics that influence the performance of radiotherapy 
programs has limited the design and management of their 
services. As a result, planning has often been directed by expert 
opinion rather than objective evidence. The consequences of 
such an approach can be unpredictable, which in turn can lead 
to inefficient and inadequate care. In an era of high-precision 
radiotherapy, the greatest imprecision is still failing to deliver 
radiotherapy when it is indicated. In order to improve the 
delivery of precision radiotherapy services, a better 
understanding of factors affecting the demand for radiotherapy 
is needed.  
We propose a study to begin to address this, focusing on lung 
cancer as an example. 
Recently, Cambridge University has developed The MALTHUS 
Project: An application of mathematical models of radiotherapy 
demand for local and national capacity planning using Monte-
Carlo simulation techniques. The MALTHUS model is a form of 
Evidence-Based Requirements Analysis (EBRA). EBRA identifies 
indications for radiation therapy for a specific population based 
on systematic literature reviews. It then used an epidemiologic 
approach to calculate how frequently these indications for 
radiotherapy occurred in the population. This information is 
synthesized in order to estimate an appropriate rate of 
radiotherapy utilization. Delaney, Barton et al. expanded its use 
to all cancer sites and EBRA-type models are now broadly used 
for resource planning. Compared to some historical EBRA models, 
the MALTHUS model has the advantage of taking into 
consideration treatment complexities and dose fractionation of 
radiotherapy, which results in a more accurate demand 
quantification.  
A second method of demand estimation, “Benchmarking,” draws 
from the business world practice of comparing outcomes against 
the toughest competitor. In a radiotherapy context, 
benchmarking utilizes regions with cancer centres without major 
access barriers as the standard. This method assumes that 
experts are making “perfect” decisions about radiotherapy 
indications and that patients have unrestricted access to 
services. Criticism of the benchmarking method to assess health 
outcomes lies in its assumption of optimal structures, processes 
and practices, all of which have not been proven. 
The overall population’s need for radiotherapy will change 
according to the different proportions of cancers and stages of 
cancer found in different populations, geography, as well as 
patient factors such as functional status, age, and comorbidity. 
To tailor the model to a specific country or health setting 
requires data on the distribution of tumour types and stages as 
well as geographical and demographic factors. The MALHTUS 
model can be used to examine factors associated with regional 
variation in current demand and can also be used to predict 
future demand. 
Proposed Study:  We propose a comparative analysis between 
Ontario and England of the estimated need for external beam 
radiotherapy for lung cancer based on the MALTHUS model. The 
analysis will provide insights characterizing the extent to which 
patient-related and disease-related factors that drive the need 
for radiotherapy resources.  
This study will build on previous models of radiotherapy 
utilization and will be a collaborative approach with multiple 
international stakeholders.  The results of this study will aim to 
optimize utilization of high-precision radiotherapy in quantifying 
the impact of patient factors, disease factors, and treatment 
factors on estimating demand of radiotherapy.   
Hypotheses:  
1) That evidence-based estimates of need for radiotherapy for 
lung cancer will vary widely between health delivery units 
